AU2019261438B2 - Expression of FOXP3 in edited CD34+ cells - Google Patents

Expression of FOXP3 in edited CD34+ cells Download PDF

Info

Publication number
AU2019261438B2
AU2019261438B2 AU2019261438A AU2019261438A AU2019261438B2 AU 2019261438 B2 AU2019261438 B2 AU 2019261438B2 AU 2019261438 A AU2019261438 A AU 2019261438A AU 2019261438 A AU2019261438 A AU 2019261438A AU 2019261438 B2 AU2019261438 B2 AU 2019261438B2
Authority
AU
Australia
Prior art keywords
cell
foxp3
sequence
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019261438A
Other languages
English (en)
Other versions
AU2019261438A1 (en
Inventor
Yuchi Chiang HONAKER
Iram F. KHAN
David J. Rawlings
Andrew M. Scharenberg
Swati SINGH
Karen SOMMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of AU2019261438A1 publication Critical patent/AU2019261438A1/en
Application granted granted Critical
Publication of AU2019261438B2 publication Critical patent/AU2019261438B2/en
Priority to AU2024266824A priority Critical patent/AU2024266824A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019261438A 2018-04-27 2019-04-25 Expression of FOXP3 in edited CD34+ cells Active AU2019261438B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024266824A AU2024266824A1 (en) 2018-04-27 2024-11-22 Expression of FOXP3 in edited CD34+ cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663545P 2018-04-27 2018-04-27
US62/663,545 2018-04-27
PCT/US2019/029082 WO2019210042A1 (en) 2018-04-27 2019-04-25 Expression of foxp3 in edited cd34+ cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024266824A Division AU2024266824A1 (en) 2018-04-27 2024-11-22 Expression of FOXP3 in edited CD34+ cells

Publications (2)

Publication Number Publication Date
AU2019261438A1 AU2019261438A1 (en) 2020-09-10
AU2019261438B2 true AU2019261438B2 (en) 2024-08-22

Family

ID=68294731

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019261438A Active AU2019261438B2 (en) 2018-04-27 2019-04-25 Expression of FOXP3 in edited CD34+ cells
AU2024266824A Pending AU2024266824A1 (en) 2018-04-27 2024-11-22 Expression of FOXP3 in edited CD34+ cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024266824A Pending AU2024266824A1 (en) 2018-04-27 2024-11-22 Expression of FOXP3 in edited CD34+ cells

Country Status (9)

Country Link
US (2) US11713459B2 (enExample)
EP (1) EP3784690A4 (enExample)
JP (2) JP7575950B2 (enExample)
CN (1) CN112218882A (enExample)
AU (2) AU2019261438B2 (enExample)
CA (1) CA3091688A1 (enExample)
IL (1) IL277039A (enExample)
SG (1) SG11202007878UA (enExample)
WO (1) WO2019210042A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016427822B2 (en) 2016-10-31 2025-01-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene
CN112218882A (zh) * 2018-04-27 2021-01-12 西雅图儿童医院（Dba西雅图儿童研究所） Foxp3在经编辑的cd34+细胞中的表达
US20210253652A1 (en) * 2018-04-27 2021-08-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
EP3912644A4 (en) * 2019-01-18 2022-09-28 Osaka University THERAPEUTIC AGENT FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA
CA3141159A1 (en) * 2019-05-21 2020-11-26 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
NZ783217A (en) * 2019-06-27 2025-08-29 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Artificial antigen-specific immunoregulatory t (airt) cells
EP4055039A1 (en) 2019-11-08 2022-09-14 Sangamo Therapeutics, Inc. Generation of engineered regulatory t cells
WO2021144692A1 (en) * 2020-01-14 2021-07-22 Crispr Therapeutics Ag Methods for increased efficiency of homology-directed repair
WO2021163642A2 (en) * 2020-02-13 2021-08-19 The Board Of Trustees Of The Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
JP4353701B2 (ja) 2001-05-08 2009-10-28 ダーウィン モレキュラー コーポレイション Ｆｏｘｐ３蛋白質を用いた霊長類における免疫機能の調節方法
GB0614536D0 (en) 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
EP2064350B1 (en) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression of foxp3 by cancer cells
US20100135974A1 (en) 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US20110123502A1 (en) * 2007-02-21 2011-05-26 Barry Simon C Method for obtaining treg-cells
WO2008141282A2 (en) 2007-05-11 2008-11-20 The Regents Of The University Of Michigan Materials and methods for foxp3 tumor suppression
WO2008154399A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Foxp3 oligomerization and intermolecular interactions
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
JP2011513403A (ja) 2008-03-03 2011-04-28 コンバージ バイオテック， インコーポレイテッド Ｔ細胞依存性免疫応答を調節する方法
WO2012018930A1 (en) 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
WO2014180943A1 (en) 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
ES2883131T3 (es) * 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
DK3004337T3 (da) 2013-05-29 2017-11-13 Cellectis Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system
JP6673838B2 (ja) 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
US20170198306A1 (en) 2014-03-21 2017-07-13 Cellectis Engineering mammalian genome using dna-guided argonaute interference systems (dais)
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
EP3245294A4 (en) 2015-01-12 2018-05-30 Massachusetts Institute of Technology Gene editing through microfluidic delivery
ES2880473T5 (es) * 2015-01-30 2024-05-09 Univ California Suministro de proteínas en células hematopoyéticas primarias
HK1254190A1 (zh) 2015-05-08 2019-07-12 President And Fellows Of Harvard College 通用供体干细胞和相关方法
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
WO2018031762A1 (en) 2016-08-10 2018-02-15 Duke University Compositions, systems and methods for programming immune cell function through targeted gene regulation
CA3034094A1 (en) * 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
WO2018073391A1 (en) * 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018081476A2 (en) 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of t cell therapy
AU2016427822B2 (en) 2016-10-31 2025-01-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene
JP7206214B2 (ja) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
CN109790518A (zh) 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
EP3672617A4 (en) * 2017-08-22 2021-06-23 The Regents of the University of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
CN112218882A (zh) * 2018-04-27 2021-01-12 西雅图儿童医院（Dba西雅图儿童研究所） Foxp3在经编辑的cd34+细胞中的表达
US20210253652A1 (en) 2018-04-27 2021-08-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOODWIN , M., et al., 2016, '123. Gene editing as a therapeutic approach to treat IPEX syndrome', Molecular Therapy, 24(1), pages S51-S52 *
KORNETE, M., et al., 2018, 'Highly efficient and versatile plasmid-based gene editing in primary T cells', Journal of Immunology, 200(7), pages 2489-2501 *

Also Published As

Publication number Publication date
EP3784690A1 (en) 2021-03-03
EP3784690A4 (en) 2022-01-19
CA3091688A1 (en) 2019-10-31
SG11202007878UA (en) 2020-09-29
CN112218882A (zh) 2021-01-12
JP7575950B2 (ja) 2024-10-31
JP2025013884A (ja) 2025-01-28
AU2019261438A1 (en) 2020-09-10
AU2024266824A1 (en) 2024-12-12
JP2021521856A (ja) 2021-08-30
US20240117352A1 (en) 2024-04-11
IL277039A (en) 2020-10-29
US20210054376A1 (en) 2021-02-25
US11713459B2 (en) 2023-08-01
WO2019210042A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
AU2019261438B2 (en) Expression of FOXP3 in edited CD34+ cells
AU2019257708B2 (en) Expression of human FOXP3 in gene edited T cells
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
KR102386029B1 (ko) 게놈 편집 면역 효과기 세포
AU2017323629B9 (en) PD-1 homing endonuclease variants, compositions, and methods of use
JP2024023294A (ja) 遺伝子編集のためのｃｐｆ１関連方法及び組成物
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
AU2020229875B2 (en) Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR102178322B1 (ko) 변형된 인자 ix, 및 세포, 기관 및 조직으로 유전자를 전달하기 위한 조성물, 방법 및 용도
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
CN112313334A (zh) 用以编辑血红蛋白相关突变的同源定向修复模板设计和递送
KR20210030973A (ko) 조작된 면역자극성 박테리아 균주 및 이의 용도
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
KR20230066000A (ko) 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
KR20180034467A (ko) L-dopa의 전신 합성 및 조절
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
TW202317753A (zh) 經武裝之嵌合受體及其使用方法
KR20230069157A (ko) GJB2를 코딩하는 재조합 아데노 연관 바이러스 (rAAV) 및 그의 용도
CN112469823A (zh) 布鲁顿氏酪氨酸激酶的基于talen和基于crispr/cas的基因编辑
CN117157109A (zh) 腺病毒基因疗法载体
HK40044016A (en) Expression of foxp3 in edited cd34+ cells
CN116997657A (zh) 编码GJB2的重组腺相关病毒(rAAV)及其用途
RU2812852C2 (ru) Невирусные днк-векторы и варианты их применения для экспрессии терапевтического средства на основе фактора viii (fviii)
NL2027815B1 (en) Genomic integration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)